BAM
DTIL icon

Blueshift Asset Management’s Precision BioSciences DTIL Stock Holding History

Blueshift Asset Management’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-600
Closed -$225K – 1071
2021
Q2 		$225K Buy
+600
New +$180K 0.01% 817

Other funds holding DTIL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Blueshift Asset Management's DTIL Position: Q3 2021 in Review

Blueshift Asset Management sold out of Precision BioSciences (DTIL) in Q3 2021, closing a stake of 600 shares — an estimated $225K sold.

Blueshift Asset Management first reported a position in DTIL in Q2 2021 and held it in 1 quarter. The position peaked at $225K in Q2 2021. 132 funds tracked by Wall St. Rank hold DTIL as of Q3 2021.

  • Blueshift Asset Management reported no remaining Precision BioSciences position as of Q3 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 600 Precision BioSciences shares in Q3 2021, an estimated $225K.
  • Blueshift Asset Management first reported a position in Precision BioSciences in Q2 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Precision BioSciences position peaked at $225K in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Precision BioSciences as of Q3 2021.

Based on Blueshift Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.